Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Snyder MA, Gao WJ.

Front Cell Neurosci. 2013 Mar 27;7:31. doi: 10.3389/fncel.2013.00031. eCollection 2013.

2.

The involvement of N-methyl-d-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.

Ju P, Cui D.

Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):209-19. doi: 10.1093/abbs/gmv135. Epub 2016 Feb 1. Review.

PMID:
26837414
3.

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Kantrowitz JT, Javitt DC.

Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Review.

4.

Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases.

Lin H, Hsu FC, Baumann BH, Coulter DA, Lynch DR.

Neurobiol Dis. 2014 Mar;63:129-40. doi: 10.1016/j.nbd.2013.11.021. Epub 2013 Dec 8.

5.

The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.

Balu DT.

Adv Pharmacol. 2016;76:351-82. doi: 10.1016/bs.apha.2016.01.006. Epub 2016 Mar 4.

PMID:
27288082
6.

Gestational methylazoxymethanol exposure leads to NMDAR dysfunction in hippocampus during early development and lasting deficits in learning.

Snyder MA, Adelman AE, Gao WJ.

Neuropsychopharmacology. 2013 Jan;38(2):328-40. doi: 10.1038/npp.2012.180. Epub 2012 Sep 12. Erratum in: Neuropsychopharmacology. 2013 May; 38(6):1142.

7.

Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.

Anderson G, Maes M.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:5-19. doi: 10.1016/j.pnpbp.2012.06.014. Epub 2012 Jul 16. Review.

PMID:
22800757
8.

Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.

Geddes AE, Huang XF, Newell KA.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):896-904. doi: 10.1016/j.pnpbp.2011.02.017. Epub 2011 Mar 1. Review.

PMID:
21371516
9.

The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.

Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J.

Front Pharmacol. 2014 Jan 2;4:169. doi: 10.3389/fphar.2013.00169. Review.

10.

NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.

Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, Tricklebank M.

Neuropharmacology. 2012 Mar;62(3):1401-12. doi: 10.1016/j.neuropharm.2011.03.015. Epub 2011 Mar 21. Review.

PMID:
21420987
11.

GABAergic interneuron origin of schizophrenia pathophysiology.

Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE.

Neuropharmacology. 2012 Mar;62(3):1574-83. doi: 10.1016/j.neuropharm.2011.01.022. Epub 2011 Jan 26. Review.

12.

Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance.

Karlsgodt KH, Robleto K, Trantham-Davidson H, Jairl C, Cannon TD, Lavin A, Jentsch JD.

Biol Psychiatry. 2011 Jan 1;69(1):28-34. doi: 10.1016/j.biopsych.2010.09.012. Epub 2010 Oct 30.

13.

Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.

Guilarte TR, Opler M, Pletnikov M.

Neurotoxicology. 2012 Jun;33(3):560-74. doi: 10.1016/j.neuro.2011.11.008. Epub 2011 Dec 9. Review.

14.

NAAG, NMDA receptor and psychosis.

Bergeron R, Coyle JT.

Curr Med Chem. 2012;19(9):1360-4. Review.

15.
16.

Regulation of N-methyl-D-aspartate receptors by disrupted-in-schizophrenia-1.

Wei J, Graziane NM, Wang H, Zhong P, Wang Q, Liu W, Hayashi-Takagi A, Korth C, Sawa A, Brandon NJ, Yan Z.

Biol Psychiatry. 2014 Mar 1;75(5):414-24. doi: 10.1016/j.biopsych.2013.06.009. Epub 2013 Jul 29.

17.

Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.

Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL, Blendy JA, Dow HC, Brodkin ES, Schneider F, Gur RC, Siegel SJ.

Genes Brain Behav. 2009 Oct;8(7):661-75. doi: 10.1111/j.1601-183X.2009.00504.x. Epub 2009 May 8.

18.

Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia.

Guo X, Hamilton PJ, Reish NJ, Sweatt JD, Miller CA, Rumbaugh G.

Neuropsychopharmacology. 2009 Jun;34(7):1659-72. doi: 10.1038/npp.2008.223. Epub 2009 Jan 14.

19.

The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.

Doreulee N, Alania M, Mitaishvili E, Chikovani M, Chkhartishvili B.

Georgian Med News. 2009 Dec;(177):59-65.

PMID:
20090156
20.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk